Get the Stockscreener App
0.9364
8.88%
0.0764
Fibrobiologics Inc stock is traded at $0.9364, with a volume of 147.09K.
It is up +8.88% in the last 24 hours and down -25.68% over the past month.
See More
Previous Close:
$0.86
Open:
$0.95
24h Volume:
147.09K
Relative Volume:
0.54
Market Cap:
$31.31M
Revenue:
-
Net Income/Loss:
$-17.78M
P/E Ratio:
-1.705
EPS:
-0.5492
Net Cash Flow:
$-10.52M
1W Performance:
-9.96%
1M Performance:
-25.68%
6M Performance:
-65.06%
1Y Performance:
-91.33%
1-Day Range:
$0.88
$0.9639
1-Week Range:
$0.86
$1.09
52-Week Range:
$0.86
$13.59
Fibrobiologics Inc Stock (FBLG) Company Profile
Name
Fibrobiologics Inc
Sector
Industry
Phone
281-671-5150
Address
455 E. MEDICAL CENTER BLVD, HOUSTON
Compare FBLG with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FBLG
Fibrobiologics Inc
|
0.9364 | 31.31M | 0 | -17.78M | -10.52M | -0.5492 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.49 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
625.60 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
583.62 | 35.60B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.83 | 34.53B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
274.78 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Fibrobiologics Inc Stock (FBLG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-12-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-30-24 | Initiated | H.C. Wainwright | Buy |
| Sep-24-24 | Initiated | Maxim Group | Buy |
Fibrobiologics Inc Stock (FBLG) Latest News
HC Wainwright Comments on FibroBiologics Q1 Earnings - Defense World
FibroBiologics gibt wissenschaftlicher Fortschritte bei der Reparatur von Hirngewebe bekannt - GlobeNewswire Inc.
FibroBiologics announces advancement in results of brain tissue repair - TipRanks
FibroBiologics Announces Scientific Advancement in Confirmation Results of Brain Tissue Repair - GlobeNewswire
Fibrobiologics Announces Scientific Advancement In Confirmation Results Of Brain Tissue Repair - MarketScreener
Major Breakthrough: FibroBiologics Confirms Brain Tissue Regeneration Success - Stock Titan
FibroBiologics’ (FBLG) “Buy” Rating Reaffirmed at D. Boral Capital - Defense World
Virtu Financial LLC Buys New Holdings in FibroBiologics, Inc. (NASDAQ:FBLG) - Defense World
FibroBiologics’ (FBLG) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Fibrobiologics stock plunges to 52-week low at $0.93 amid market challenges By Investing.com - Investing.com South Africa
Fibrobiologics stock plunges to 52-week low at $0.93 amid market challenges - Investing.com India
FibroBiologics Reports Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire
FibroBiologics Slashes Annual Losses by $5.3M as Key Clinical Trial Approaches - Stock Titan
Spotting Winners: TopBuild (NYSE:BLD) And Home Builders Stocks In Q4 - The Globe and Mail
FibroBiologics Announces 2025 Annual Meeting of Stockholders - GlobeNewswire
Biotech Pioneer FibroBiologics Reveals Massive 160+ Patent Portfolio at Upcoming Shareholder Meeting - Stock Titan
Applied Industrial (AIT): Buy, Sell, or Hold Post Q4 Earnings? - The Globe and Mail
3 Reasons to Avoid FUBO and 1 Stock to Buy Instead - The Globe and Mail
Intuitive Machines Stock (LUNR) Lifts Off with 30% Surge Post Q4 Results - The Globe and Mail
FibroBiologics to Present at The German-Nordic Joint Extracellular Matrix Meeting - GlobeNewswire
FibroBiologics Announces Presentation on Innovative Fibroblast-Based Therapeutics at The German-Nordic Joint Extracellular Matrix Meeting - Nasdaq
FibroBiologics Reveals Groundbreaking Fibroblast Treatment Targeting 7 Major Diseases - Stock Titan
FBLG stock touches 52-week low at $0.98 amid sharp annual decline By Investing.com - Investing.com South Africa
FBLG stock touches 52-week low at $0.98 amid sharp annual decline - Investing.com Australia
Life Sciences Investor Forum Agenda Announced for March 13th - GlobeNewswire
FibroBiologics files patent application for fibroblast-based therapeutics - TipRanks
FibroBiologics Files Patent For Novel Approach to Modulate Mitochondrial Activity Using Fibroblast-based Therapeutics - GlobeNewswire
Could FibroBiologics' New Mitochondrial Therapy Patent Transform Treatment for Chronic Diseases? - StockTitan
FibroBiologics’ (FBLG) Buy Rating Reiterated at D. Boral Capital - Defense World
FibroBiologics and Charles River Announce Completion and - GlobeNewswire
FibroBiologics and Charles River complete master cell bank for clinical trials - TipRanks
FibroBiologics Completes Master Cell Bank for CYWC628 in Collaboration with Charles River Laboratories - Nasdaq
FibroBiologics and Charles River Announce Completion and Release of CYWC628 Master Cell Bank for the Manufacturing of Fibroblast Cell-based Wound Healing Therapeutic - GlobeNewswire
Can This New Cell Therapy Breakthrough Finally Solve the Diabetic Foot Ulcer Crisis? - Stock Titan
FibroBiologics (FBLG) Expected to Announce Earnings on Thursday - Defense World
Fibrobiologics stock plunges to 52-week low of $1.04 By Investing.com - Investing.com Australia
Fibrobiologics stock plunges to 52-week low of $1.04 - Investing.com India
FBLG: Analyst Day Provides In-Depth Overview of Pipeline… - Zacks Small Cap Research
FibroBiologics' (FBLG) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
FibroBiologics’ (FBLG) Buy Rating Reiterated at HC Wainwright - Armenian Reporter
Exploring Growth Opportunities In FibroBiologics Inc (NASDAQ: FBLG) - Stocks Register
D. Boral Capital Reaffirms “Buy” Rating for FibroBiologics (NASDAQ:FBLG) - Defense World
Should This Give FibroBiologics Inc (NASDAQ: FBLG) Investors Sleepless Nights? - Stocks Register
FibroBiologics Inc (FBLG) stock analysis: A comprehensive overview - US Post News
FBLG (FibroBiologics Inc) may reap gains as insiders became active recently - Knox Daily
FBLG Stock Price and Chart — NASDAQ:FBLG - TradingView
FibroBiologics issues shares to fulfill commitment fee - MSN
FibroBiologics issues shares to fulfill commitment fee By Investing.com - Investing.com Australia
FibroBiologics Inc (FBLG) Stock: Navigating a Year of Volatility - The InvestChronicle
FibroBiologics Inc (NASDAQ: FBLG) Has Decreased By -81.41 Percent This Year. Is It A Better Buy Than Others? - Marketing Sentinel
Should You Invest in FibroBiologics Inc (FBLG) Now? - The News Heater
Fibrobiologics Inc Stock (FBLG) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):